We are live on ! Find out more

Direxion Daily S&P Biotech Bull 3X ETF

LABU

Market cap $587M

223.75 USD

+15.13

7.25%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

224.00

+0.25

0.11%

1 day

7.25%

5 days

-10.23%

1 month

-3.12%

3 months

-14.7%

6 months

10.13%

Year to date

42.06%

1 year

88.33%

5 years

-81.51%

10 years

-63.08%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 50%

Negative 0%

24/7 Wall Street

Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million

Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.

Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Medical Technology Stocks: Innovation Endures As Valuations Reset

24/7 Wall Street

LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout

If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%.

LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout

24/7 Wall Street

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now

Biotech has reasserted itself over the past year as drug approvals,

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now

24/7 Wall Street

Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026

Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move.

Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026

Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs

Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail.

Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs

Top Performing Leveraged/Inverse ETFs: 11/16/2025

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Top Performing Leveraged/Inverse ETFs: 11/16/2025

New FDA Director Could Sway Biotech ETFs

Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience.

New FDA Director Could Sway Biotech ETFs

Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Investing In Health Stocks - How Policy Clarity Is Opening Doors

See News Rankings

Price charts implemented using Lightweight Charts™